Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 10,356 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all

Conditions: End Stage Renal Disease, Hyperhomocysteinemia
Interventions: cyanocobalamin, folic acid, pyridoxine; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 89 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Epidermolysis Bullosa
Interventions: Serlopitant Tablet, Placebo Oral Tablet; Drug
Lead sponsor: Stanford University; Other
Eligibility: 13 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Atopic Dermatitis
Interventions: 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2; Drug
Lead sponsor: Amytrx Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Cerritos, California • Encino, California • Long Beach, California + 8 more

Conditions: Osteogenesis Imperfecta
Interventions: Invisalign; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 40 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Bethesda, Maryland

Conditions: MDS, Immunodeficiency, GATA2
Interventions: Cyclophosphamide (CTX, Cytoxan), Fludarabine(Fludara,Berlex Laboratories), Total Body Irradiation (TBI), Allogeneic Hematopoietic Stem Cell (HSC), Equine Anti-Thymocyte Globulin; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperlipidemia, Mixed Hyperlipidemia, Dyslipidemia
Interventions: Niacin Extended Release/Lovastatin; Drug
Lead sponsor: In His Image; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Gout
Interventions: Not listed
Lead sponsor: jasvinder singh; Federal
Eligibility: 18 Years to 110 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure
Interventions: 95% - 99% SpO2 target; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 0 Days to 28 Days
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: GM2 Gangliosidosis, Tay-Sachs Disease, Sandhoff Disease
Interventions: IB1001; Drug
Lead sponsor: IntraBio Inc; Industry
Eligibility: 6 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York

Conditions: Duodenal Adenomas, Familial Adenomatous Polyposis
Interventions: CryoBalloon ablation; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 4
States / cities: Baltimore, Maryland • Manhasset, New York • Danville, Pennsylvania + 1 more

Conditions: Congenital Heart Disease
Interventions: Use of prebypass ultrafiltration (PBUF); Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Day to 1 Year
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Interventions: Cefiderocol; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Hartford, Connecticut • Indianapolis, Indiana • Pittsburgh, Pennsylvania + 1 more

Conditions: Sickle Cell Trait
Interventions: SCT Documentation and Disclosure Toolkit (SCT-DD); Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: Not listed
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Muscular Dystrophy, Facioscapulohumeral
Interventions: Clenbuterol; Drug
Lead sponsor: Jeffrey Statland; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Kansas City, Kansas • Rochester, New York • Seattle, Washington

Conditions: Down Syndrome, Obstructive Sleep Apnea
Interventions: Family-informed intervention, Standard Clinical Care; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 6 Years to 18 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Retinitis Pigmentosa
Interventions: RETINA IMPLANT Alpha AMS; Device
Lead sponsor: Wills Eye; Other
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ventricular Septal Defects
Interventions: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 48
States / cities: Phoenix, Arizona • Los Angeles, California • Madera, California + 40 more

Conditions: Lysosomal Acid Lipase Deficiency
Interventions: Sebelipase Alfa, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 11
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 8 more

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Surfactant; Drug
Lead sponsor: Sood, Beena G., MD, MS; Individual
Eligibility: Up to 24 Hours
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cancer
Interventions: captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Genetic Disease, STXBP1 Encephalopathy With Epilepsy, SYNGAP1-Related Intellectual Disability
Interventions: Non-interventional study; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • New York, New York + 2 more

Conditions: Sickle Cell Disease
Interventions: Prasugrel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 20
States / cities: Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more

Conditions: Friedreich Ataxia, Cardiomyopathies, Cardiac Hypertrophy, Myocardial Fibrosis
Interventions: AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN, Prednisone; Biological · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 12 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Congenital Heart Disease
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1980 – 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Clear Aligners for the Treatment of Dental Malocclusion in OI

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care

CLinical Prediction Rule Score in Veterans

Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hypertension

N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)

CryoBalloon Ablation for Treatment of Duodenal Adenomas

Pre Bypass Ultrafiltration (PBUF) in Children Requiring Cardiopulmonary Bypass

Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis

Increasing Documentation and Disclosure of Sickle Cell Trait Status: An Implementation Science Approach

Clenbuterol to Target DUX4 in FSHD

Positive Airway Pressure (PAP) for Children With Down Syndrome (DS) and Obstructive Sleep Apnea Syndrome (OSAS)

RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa

Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency

Aerosolized Surfactant in Neonatal RDS

Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation

STXBP1 and SYNGAP1 Related Disorders Natural History Study

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

Hepatitis C in Adults Who Underwent Congenital Heart Surgery Before Screening